Research programme: deuterium stabilised enantiomers - DeuteRx

Drug Profile

Research programme: deuterium stabilised enantiomers - DeuteRx

Alternative Names: Deuterated bupropion; Deuterated CC11006; Deuterated inolitazone; Deuterated mitoglitazone; Deuterated MSDC 0160; Deuterated pioglitazone; Deuterium stabilised enantiomer bupropion; Deuterium stabilised enantiomer CC 11006; Deuterium stabilised enantiomer inolitazone; Deuterium stabilised enantiomer mitoglitazone; Deuterium stabilised enantiomer MSDC 0160; Deuterium stabilised enantiomer pioglitazone; DRX 065; DRX 184; DRX 195; DRX-164; DRX-194

Latest Information Update: 24 Aug 2016

Price : $50

At a glance

  • Originator DeuteRx
  • Developer Celgene Corporation; DeuteRx
  • Class Indans; Piperidines; Small molecules; Thiazolidinediones
  • Mechanism of Action Acetylcholinesterase inhibitors; Adrenergic receptor antagonists; Carrier protein inhibitors; Dopamine uptake inhibitors; Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Mitochondrial protein inhibitors; Mitochondrial protein stimulants; Peroxisome proliferator-activated receptor gamma agonists; Platelet ADP receptor antagonists; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Adrenoleucodystrophy; Adrenomyeloneuropathy; Non-alcoholic steatohepatitis
  • Research Acute coronary syndromes; Alzheimer's disease; CNS disorders; Colorectal cancer; Inflammation; Major depressive disorder; Multiple myeloma; Myelodysplastic syndromes; Sickle cell anaemia; Type 2 diabetes mellitus

Most Recent Events

  • 22 Aug 2016 Preclinical trials in Adrenomyeloneuropathy in USA
  • 22 Aug 2016 DeuteRx plans a phase Ia trial in Healthy volunteers in USA
  • 22 Aug 2016 US FDA approves IND application for DRX 065 in Adrenomyeloneuropathy and Non-alcoholic Steatohepatitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top